EBRT + TLX101 Aids Patients with Brain Tumors Free

Telix Pharmaceuticals announced that TLX101 (¹³¹I-iodofalan) increased median overall survival (OS) for patients with high-grade glioma, when compared against median OS without the drug. In the phase II IPAX-Linz study, eight patients received TLX101––which targets L-type amino acid transporter 1, a protein overexpressed in some gliomas, including glioblastoma––in combination with external beam radiation therapy (EBRT). These patients had a median OS of 12.4 months; the median OS in patients treated with EBRT alone is about 10 months.